Grant of Options under Long Term Incentive Scheme
Allergy Therapeutics plc announced on January 28, 2026, that it granted share option awards to key management personnel, including persons discharging managerial responsibilities, on January 27, 2026. These options are designed to incentivize long-term value creation and align management interests with stakeholders, with 70% vesting based on Adjusted EBITDA performance and 30% on share price performance over a three-year period. The Chief Executive Officer received 5,409,724 options, and the Chief Financial Officer received 2,489,627 options, both with an exercise price of £0.001. Following these grants, the company has options outstanding over 365,205,852 ordinary shares, representing 5.95% of its current issued share capital.
Select text to share a quote on X · sign in to keep highlights & notes in your AGY notes
28 January 2026: Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapies, today announces that on 27 January 2026 it granted share option awards to key members of Allergy Therapeutics' management team including certain of its persons discharging managerial responsibilities ("PDMRS").
The Board has granted options to encourage long-term value creation for the Company's shareholders, and so that the individuals identified as key people to lead the business into the future are appropriately incentivised in a manner that aligns with the interests of the Group's stakeholders.
Vesting is conditional on the satisfaction of performance criteria over a three-year period. Vesting of 70 per cent. of the award subject to Adjusted EBITDA* performance and vesting of the remaining 30 per cent. of the award is subject to share price performance.
The following awards have been made in accordance with the Group LTIP:
| Name | Title | Number of share options granted | Resultant number of share options held | Performance period | Vesting Date | Exercise price | Number of Ordinary Shares held |
|---|---|---|---|---|---|---|---|
| Manuel Llobet | Chief Executive Officer | 5,409,724 | 142,578,024 | 3 years commencing 1 July 2025 | 30 June 2028 | £0.001 | 5,001,200 |
| Shaun Furlong | Chief Financial Officer | 2,489,627 | 21,704,724 | 3 years commencing 1 July 2025 | 30 June 2028 | £0.001 | 1,507 |
The number of Ordinary Shares stated above is the maximum number that could be issued to each PDMR upon full satisfaction of the performance conditions attached to the awards.
The Group's Remuneration Committee will review the performance conditions at periodic intervals to ensure they remain appropriate. As a result of any such review, the Committee will retain discretion to amend the conditions where appropriate having regard to overall Company performance and wider stakeholder experience.
Following the above grants of options, the Company has options outstanding over 365,205,852 ordinary shares, representing 5.95% of the Company's current issued share capital.
*Adjusted EBITDA means earnings before interest, taxes, depreciation and amortisation adjusted to exclude the impact of R&D expenditure, exceptional items, equity settled long term incentive plans and gains or losses arising on fundraising activities. The Committee may, in its absolute discretion, make further adjustments to the Adjusted EBITDA figure disclosed in the Company's audited consolidated accounts for the relevant financial year, so that the Adjusted EBITDA figure fairly reflects underlying Group financial performance. Adjustments may include, but are not limited to, the cost of long-term strategic investments, approved after the relevant performance condition was set, with a short-term negative impact on Adjusted EBITDA in the relevant financial year. Such adjustments will be applied on a logical, transparent and consistent basis.
| a) | Name | Manuel Llobet |
| 2 | Reason for the notification | |
| a) | Position/status | Chief Executive Officer |
| b) | Initial notification /Amendment | Initial notification |
| a) | Name | Allergy Therapeutics plc |
| b) | LEI | 213800PQ7AHK7KGVOE23 |
| a) | Description of the financial instrument, type of instrument | Ordinary shares of 0.1 pence each |
| Identification code | GB00B02LCQ05 | |
| b) | Nature of the transaction | Grant of options |
| c) | Price(s) and volume(s) | Exercise Price per share Volume £0.001 5,409,724 |
| d) | Aggregated information - Aggregated volume - Price | See 4c) above |
| e) | Date of the transaction | 27 January 2026 |
| f) | Place of the transaction | Outside a trading venue |
| 1 | Details of the persons discharging managerial responsibilities / person closely associated | |
| a) | Name | Shaun Furlong |
| 2 | Reason for the notification | |
| a) | Position/status | Chief Financial Officer |
| b) | Initial notification /Amendment | Initial notification |
| a) | Name | Allergy Therapeutics plc |
| b) | LEI | 213800PQ7AHK7KGVOE23 |
| a) | Description of the financial instrument, type of instrument | Ordinary shares of 0.1 pence each |
| Identification code | GB00B02LCQ05 | |
| b) | Nature of the transaction | Grant of options |
| c) | Price(s) and volume(s) | Exercise Price per share Volume £0.001 2,489,627 |
| d) | Aggregated information - Aggregated volume - Price | See 4c) above |
| e) | Date of the transaction | 27 January 2026 |
| f) | Place of the transaction | Outside a trading venue |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.